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7RESEARCH ARTICLE Open AccessCisplatin-resistant cells in malignant pleural
mesothelioma cell lines show ALDHhighCD44+
phenotype and sphere-forming capacity
Lourdes Cortes-Dericks, Laurene Froment, Ruben Boesch, Ralph Alexander Schmid* and Golnaz KaroubiAbstract
Background: Conventional chemotherapy in malignant pleural mesothelioma (MPM) has minimal impact on
patient survival due to the supposed chemoresistance of cancer stem cells (CSCs). We sought to identify a
sub-population of chemoresistant cells by using putative CSC markers, aldehyde dehydrogenase (ALDH) and CD44
in three MPM cell lines; H28, H2052 and Meso4.
Methods: The Aldefluor assay was used to measure ALDH activity and sort ALDHhigh and ALDHlow cells.
Drug-resistance was evaluated by cell viability, anchorage-independent sphere formation, flow-cytometry and
qRT-PCR analyses.
Results: The ALDHhigh - and ALDHlow -sorted fractions were able to demonstrate phenotypic heterogeneity and generate
spheres, the latter being less efficient, and both showed an association with CD44. Cis- diamminedichloroplatinum (II)
(cisplatin) treatment failed to reduce ALDH activity and conferred only a short-term inhibition of sphere
generation in both ALDHhigh and ALDHlow fractions of the three MPM cell lines. Induction of drug sensitivity by
an ALDH inhibitor, diethylaminobenzaldehyde (DEAB) resulted in significant reductions in cell viability but not a
complete elimination of the sphere-forming cells, suggestive of the presence of a drug-resistant subpopulation.
At the transcript level, the cisplatin + DEAB-resistant cells showed upregulated mRNA expression levels for
ALDH1A2, ALDH1A3 isozymes and CD44 indicating the involvement of these markers in conferring
chemoresistance in both ALDHhigh and ALDHlow fractions of the three MPM cell lines.
Conclusions: Our study shows that ALDHhigh CD44+ cells are implicated in conveying tolerance to cisplatin in
the three MPM cell lines. The combined use of CD44 and ALDH widens the window for identification and
targeting of a drug-resistant population which may improve the current treatment modalities in mesothelioma.
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Malignant pleural mesothelioma is an aggressive tumour
with a very poor prognosis [1]. The combination of
pemetrexed and cisplatin is considered the front-line
regimen for this disease, yielding a response rate of 41%
and a median survival of 12.1 months [2]. Despite con-
tinuous efforts to implement new therapeutic modalities,
none of these, have prolonged patient survival primarily
due to chemoresistance [1]. It has been hypothesized
that tumour relapse may be associated with the drug* Correspondence: ralph.schmid@insel.ch
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article, unless otherwise stated.resistance of cancer stem cells; a rare cell population
with the exclusive ability to self- renew and maintain a
tumour [3]. Hence, the identification and complete elim-
ination of these cells presents an ultimate goal in MPM
therapy. Current studies have identified ALDH and
CD44 as putative CSC markers which exhibit high che-
moresistive properties in solid cancers; thus, rendering
them as potential indicators of drug tolerance in MPM.
Aldehyde dehydrogenase enzymes are a family of
intracellular enzymes that are involved in cellular prolif-
eration, differentiation, detoxification, and drug resist-
ance through the oxidation of cellular aldehydes [4,5].
Certain ALDH isozymes are upregulated in tumour cellsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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phamides and some oxazaphosphorines leading to de-
creased chemotherapeutic effect. In leukemia and lung
cancer cell lines overexpression of ALDH1A2a and
ALDH2 increased cell proliferation and resistance to 4-
hydroperoxicyclophosphamide and doxorubicin indicat-
ing a role for the ALDH isozymes in drug resistance [6].
The modulation of ALDH activity has been a central
subject of research to improve the efficacy of conven-
tional chemotherapeutic drugs. Studies have shown that
in small cell lung cancer, lung adenocarcinoma, leukemia
and lung cancer cell lines the ALDH-dependent che-
moresistance can be inhibited by DEAB or siRNA that
conferred sensitivity to drug treatments [7-9].
CD44, a transmembrane receptor for hyaluronan is as-
sociated with aggressive tumour growth, metastasis and
resistance to therapy [10,11]. In combination with other
surface markers (e.g., ALDH and CD24), CD44 can
discriminate between various cancer subsets. In solid
cancers the ALDHhigh/CD44+ subpopulation has been
shown to possess stem cell-like properties that convey
radio- and chemoresistance [12-14]. ALDH+/CD44+ sub-
population can be sensitized by selective inhibition of
ALDH activity using DEAB or all-trans retinoic acid,
ATRA in breast cancer [14]. As a single marker, CD44 is
currently considered as a putative CSC indicator in hu-
man carcinomas including cancer of the lung. In NSCLC
cell lines, sorted CD44+ cells that bear stem cell-like prop-
erties conferred more resistance to cisplatin exhibiting
lower apoptotic levels compared with CD44− cells [15].
Despite the current evidence linking ALDH and CD44
to drug resistance in solid tumours, the variability in the
different studies still warrants further investigation to
delineate the present roles of these potential CSC
markers. Here, we sought to investigate whether ALDH
can select for a drug-resistant subpopulation in three
MPM cell lines. We also assessed whether the ALDHhigh
cells were associated with CD44, thus broadening the
spectrum for identification of a drug-tolerant subpopula-
tion in MPM. The specific selection of a chemoresistant
subpopulation using ALDH and CD44 may serve as a
potential therapeutic target that may be employed as ad-
juvant therapy to the current standard treatment modal-
ities in MPM.
Methods
Cell culture
The H28 and H2052 mesothelioma cell lines (LCD Pro-
mochem, France) were maintained in RPMI 1640 (PAA,
Austria) containing 10% fetal bovine serum, FBS (PAA,
Austria) and 1% penicillin/streptomycin solution (Invitrogen,
Switzerland). ACC-Meso-4 cell line was purchased from
Riken Cell Bank, Resource No: RBRC-RCB2293 (Ibaraki,
Japan) and cultured using the above-mentioned culturemedium. Cells were cultured at 37°C, 95% humidity and
5% C02. The general information issued by the providers
of the three MPM cell lines does not have data on drug
resistance to cisplatin.Sphere formation
Single-cell preparations of parental and ALDH-sorted
MPM cell lines were resuspended in an appropriate
amount of sphere-forming medium (RPMI1640 supple-
mented with 20 ng/ml EGF and bFGF, [Invitrogen,
Switzerland]; 4 μg/ml insulin, [Sigma, Germany]; 1 ml
B27, [Invitrogen, Switzerland] and 1% penicillin/strepto-
mycin solution). For all cell lines, 5 x 103 cells/ml/well
were seeded onto a 24-well ultra-low adherent plate
(Costar, USA). Cells were incubated at 37°C, 95% humid-
ity and 5% C02 for 7–14 days. The documentation of
images and evaluation of sphere-forming efficiency were
performed on day 7. Sphere-forming efficiency (%) was
determined by dividing the number of spheres formed
by the original number of seeded cells. The quotient was
then multiplied by 100 [16]. Images were taken with
Leica DMI 4000B at 5x magnification.Drug treatment
Drug resistance to cisplatin of mesothelioma cells were
assessed by exposure to the IC50 values obtained for the
non-sorted and ALDH-sorted cells for each of the three
MPM cell lines. For the determination of IC50, a dilution
series of 2-fold increments of cisplatin (0–256 μM Cis-
platin, CDDP, Bristol Myers Squibb, Switzerland) were
prepared in RPMI 1640 supplemented with 10% FBS
and 1% penicillin/streptomycin. Cells at a density of 5 x
103cells/100 μl/well in 96-well plates were incubated in
media with or without the addition of cisplatin. Fol-
lowing a 48- and 72-hr incubation periods, culture
media was aspirated, then replenished with XTT cell
proliferation assay (Roche Chemicals, Switzerland) re-
agents. After a 30-min incubation at 37°C, formazan
production was measured spectrophotometrically at
450 nm. Three independent experiments in triplicate
were performed.
For cisplatin treatment, cells were cultured at 5 x 104
cells/well in a 6-well plate (in three replicates) 48 hours
prior to the addition of the previously determined IC50
of cisplatin for each cell line in RPMI 1640 containing
10% FBS and 1% penicillin/streptomycin solution. Fol-
lowing the 48- and 72-h hour treatments at 37°C, cells
were washed with PBS and harvested to perform the
following: mRNA isolation, sphere formation assay and
cell viability. Pre-treatment of cells with 100 μM of
ALDH inhibitor, DEAB (Sigma, Germany) was done for
48 h prior to cisplatin treatment [6,14].
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The Aldefluor kit (Stem Cell Technologies, Canada) was
used to identify the cells expressing ALDH activity. Cells
(0.5 – 1.0 x 106) were incubated in assay buffer containing
ALDH substrate BODIPY-aminoacetaldehyde (BAAA). As
negative control, an aliquot of the ALDH substrated-
treated cells were immediately quenched with specific
ALDH inhibitor, DEAB. Both tubes were incubated for
45 min at 37°C. After incubation, cells were centrifuged
and the pellets were resuspended with 500 μl of assay buf-
fer prior to data acquisition using the green fluorescence
channel of the LSR II flow cytometer (Becton Dickinson).
This flow cytometry-based assay is termed as FACS
analysis in this manuscript. DEAB-treated cells served as
control to set the ALDHhigh regions. The same staining
procedure was applied before sorting the cells with FACS
Aria using FACS Diva software (Becton Dickinson). Cell
purity was determined at each independent sorting. After
sorting of the ALDHhigh and ALDHlow fractions, these
were immediately used in all experiments. ALDHhigh
CD44+ phenotype was assessed by immediately re-
staining the freshly-sorted ALDHhigh and ALDHlow cells
with mouse anti-human CD44 APC-H7 (clone G44-26,
BD Pharmingen, USA) and appropriate isotype control
(mouse IgG2bK) for 30 min on ice in the dark. After
washing with FACS buffer, data acquisition followed
immediately. Propidium iodide (PI) staining was used
to exclude the non-viable cells. FACS data were ana-
lysed with Flowjo software 7.2.5 (Treestar, Oregon,
USA).RNA extraction and real-time quantitative PCR
Cell cultures were collected in an appropriate amount of
RNAprotect™ cell reagent (Qiagen, Germany) followed
by total RNA extraction using RNeasy Kit ( Qiagen) ac-
cording to manufacturer’s instructions. Complementary
DNA (cDNA) was synthesized by using the High capacity
cDNA reverse transcription kit (Applied Biosystems,
Rotkreuz, Switzerland) following the manufacturer’s in-
structions. The mRNA levels of the housekeeping gene
β2-microglobulin, β2M, and the target genes ALDH1A1,
ALDH1A2, ALDH1A3, ALDH2 and CD44 were quanti-
fied with the commercially available TaqMan “Assay on
Demand” primer/probes (β2M – Hs 99999903_m1;
ALDH1A1 –Hs 00167445_m1; ALDH1A2- Hs 0018025_m1;
ALDH1A3 –Hs 00167476_m1; ALDH2 – Hs 010007998_ml;
CD44 –Hs01075861_m1) (Applied Biosystems; Rotkreuz,
Switzerland). Twenty nanograms of resulting cDNAs
were subjected to quantitative RT-PCR, in a 10 μl final
reaction volume and analyzed in triplicates. Gene ex-
pression was detected using ABI 7900 sequence detec-
tion system. The gene expression level of each target
gene was normalized by the endogeneous gene, β2Mand compared among cells by the ΔΔCT method. Base-
line and threshold for Ct calculation were set automat-
ically with ABI Prism SDS 2.1 software.
Statistical analysis
Statistical analyses were performed using Graph Pad
Prism 5.0 software© (San Diego, Ca). Two-tailed Student’s
t-test was used to compare 2 groups. One- or two-way
ANOVA with Bonferroni post hoc test as appropriate was
performed to compare the values of >2 groups. The
statistical significance was set at p <0.05.
Results
MPM cell lines exhibit sphere-forming cells and show
different degrees of ALDH activity
We initially investigated for the presence of sphere-
forming cells in the H28, H2052 and Meso4 MPM cell
lines as tumour spheroids are believed to contain putative
CSCs which may play a crucial role in chemoresistance
[12,15,17-19]. Under anchorage-independent culture con-
ditions, we found that all three MPM cell lines contained
a cell population that generated spheres of different sizes
(Figure 1A) with varying sphere-forming efficiencies
(Table 1). On days 7–10, 1st generation spheres were
dissociated into single cells, resuspended in the sphere-
forming media and observed for subsequent sphere
generation. This was repeated until the 3rd generation
spheres were established. Our data showed that all of
the MPM cell lines contained sphere-forming cells with
the ability to produce spheres up to the 3rd generation
demonstrating self-renewal properties (Figure 1B).
These findings provided evidence of the presence of pu-
tative CSCs which led us to identify these cells using the
ALDH activity, a potential CSC marker in the lung be-
lieved to be partially responsible for resistance to cancer
therapy [8,20]. Using the Aldefluor assay we measured
varying percentages of ALDH+ cells in H28 (2.29% ±
1.6), H2052 (0.82 ± 0.32) and Meso4 (12.68 ± 7.3). Rep-
resentative images of flow cytometry-based ALDH
activity are shown in Figure 2A.
ALDHhigh and ALDHlow fractions show association with
CD44
As has been described in a number of studies in solid tu-
mours [4,8,18], we used the flow cytometry-based Alde-
fluor assay (Figure 2B) to select ALDHhigh and ALDHlow
subpopulations in order to demarcate a non-CSC from a
CSC-like cell population in MPM cell lines, and deter-
mine the potential role of the former in chemoresis-
tance. We also assessed whether the ALDH-sorted
fractions co-express CD44 which would reveal a linkage
between the two markers (Figure 2C). We found high
percentages of ALDH cells co-expressing CD44 in the
ALDHhigh fractions of H28 (59.7%), H2052 (51.6%) and
Figure 1 MPM cell lines contain sphere-forming cell population. (A) H28, H2052 and Meso4 grown under anchorage-independent culture
conditions at 5000 cells/ml/well generated spheres of varying sizes and showed different sphere-forming efficiencies. (B) Representative images
of sphere formation taken on day 7 on three consecutive generations.
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fractions also co-expressed CD44 although at much
lower frequencies in H28 (1.8%), H2052 (2.0%) and
Meso4 (1.1%) relative to all cancer cells. Taken together
our data show the presence of ALDHhighCD44+ subpop-
ulations indicating an association of ALDH with CD44
within the ALDHhigh and ALDHlow fractions of the three
MPM cell lines.
ALDHhigh fractions show higher ALDH activity and
generate robust, fast-growing sphere-forming cells
We evaluated ALDH activity as well as the sphere-
forming efficiency after the in vitro expansion of ALDH-Table 1 Sphere-forming efficiency of the three MPM cell lines
Cell line Sphere generation Sphere size (μm)
H28 1° 50 - 120
2° 40 - 100
3° 40 - 100
H2052 1° 100 - 600
2° 120 - 500
3° 100 - 500
Meso4 1° 80 - 600
2° 40 – 500
3° 40 - 500
Single-cell suspensions of H28, H2052 and Meso4 were seeded at 5 x 103/well/ml o
the number of spheres formed by the original seeded cells. The quotient was thensorted cells up to four passages. We determined ALDH
activity at every passage and calculated the average in-
crease from the four passages (P1-P4), which was com-
pared with the non-sorted cells. The ALDHhigh -sorted
fractions showed a higher capacity to repopulate ALDH+
cells compared to the ALDHlow cells. Compared with the
non-sorted cell lines (P0) we found significant 4.4, 4.0 and
1.9 - fold increases in the ALDHhigh-sorted H28, H2052
and Meso4 cell lines respectively. There were no significant
differences between the ALDHlow cells and the non-sorted
controls (Figure 3A). The ALDHhigh cells and a much
lower capacity of the ALDHlow-sorted cells showed
multilineage differentiation, and an ability to preserveSphere number/SD Sphere efficiency (%)
51/17.8 1.0
47.7/4.9 0.95
20/5.0 0.40
11.5/5.7 0.23
20/6.2 0.40
25/7.4 0.50
14/5.7 0.28
12.5/5.3 0.25
10/5.0 0.20
nto a 24-well plate. Sphere-forming efficiency (%) was determined by dividing
multiplied by 100.
Figure 2 (See legend on next page.)
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Figure 2 Detection of ALDH activity and ALDHhighCD44+ cells within the ALDHhigh and ALDHlow fractions of the three MPM cell lines.
(A) Representative FACS analysis of ALDH activity in H28, H2052 and Meso4 using Aldefluor assay. Baseline control of ALDH fluorescence was
established by the addition of ALDH inhibitor, DEAB (+DEAB) and used to provide the ALDHhigh region for cells without DEAB (− DEAB). The
same gating principle was applied to sort for ALDHhigh cells. (B) Representative FACS-based sorting of ALDHhigh and ALDHlow fractions for H2052.
The non-viable cells (PI+ cells) were excluded before gating the ALDHhigh cells. In all cases, ALDHlow cells represent <4% of the dimmest cells
relative to the analysed population. Average purity of ALDHhigh cells was ≥98%. (C) The freshly-sorted ALDHhigh and ALDHlow fractions were
immediately re-stained with CD44 APC-H7 antibody to determine the co-expression of ALDH and CD44. The same procedures were employed
for ALDH sorting of H28 and H2052 cell lines and to determine the co-expression of ALDH and CD44. Three independent experiments were done
for each cell line.
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images of flow cytometry-based ALDH activity analysed at
every passage are shown in Figure 3B. We also tested the
ability of ALDHhigh and ALDHlow cells to produce spheres
up to 4 generations under the anchorage-independent
growth conditions. We observed a slight increase in theFigure 3 Effect of ALDH sorting on ALDH activity and sphere-forming
expansion. (A) The ALDH activity of the in vitro-expanded ALDHhigh and A
ALDH activity of the non-sorted cell lines, whereas P1-P4 accounts for the a
(B) Representative FACS analyses of ALDH activity of ALDH-sorted fractions
efficiency was also assessed after the in vitro expansion of the ALDHhigh an
cell culture conditions and were counted on day 7 for all cell lines and we
Methods. (D) Representative images of the sphere formation of ALDH-sorte
and SDs of 3 independent experiments for each cell line. Results were statisphere-forming efficiency of ALDHhigh fractions com-
pared with the non-sorted cells. There were no differences
in the ALDHlow fractions compared with the non-treated
controls (Figure 3C). Notably, the spheres generated by
the ALDHhigh fractions in all of the cell lines grew faster,
were larger and more robust under mechanical agitationsefficiency in H28, H2052 and Meso4 cell lines after in vitro
LDHlow fractions was determined by Aldefluor assay. P0 represents the
verage ALDH activity measured after 4 passages of in vitro expansion.
of H2052 measured at every passage. (C) The sphere-forming
d ALDHlow fractions. Cells were grown under anchorage-independent
re used to determine the sphere-forming efficiency as described in the
d fractions of H2052 taken at every passage. Results reflect the means
stically significant if p <0.05 (*p <0.05, **p <0.01).
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and non-treated controls. Representative images of
sphere formation taken at every passage are shown in
Figure 3D.
Cisplatin does not inhibit ALDH activity and sphere
formation in both ALDHhigh and ALDHlow fractions
Considering the reported involvement of ALDH in the
chemoresistance of different neoplasms [7,8,12,20,21], we
assessed the drug response of ALDH-sorted fractions of
the three MPM cell lines to the platinum-based chemo-
therapeutic drug, cisplatin, a standard drug in the treat-
ment of MPM [1]. After 48- and 72-h treatments with the
IC50 cisplatin: H28
high 28 μM, H28low 8 μM; H2052high
83 μM, H2052low 27 μM; Meso4high 27 μM, Meso4low
9 μM (see Additional file 1), ALDH activity was deter-
mined by FACS analysis and compared with those of the
non-treated cells. The relative enrichment as a result of
drug treatment was taken as an indication of drug resist-
ance of a cell population [22]. Despite the notable de-
crease in cell viability after cisplatin treatments in all of
the ALDH-sorted cells of the three MPM cell lines (see
Additional file 2), we found that 48-h drug treatment of
the ALDH-sorted fractions in H28, H2052, and Meso4
showed greatly increased ALDH activity which decreased
after 72-h drug exposure in H28 and Meso4 (Figure 4A,
C). This effect was not observed in H2052 (Figure 4B).
Our data show that the drug resistance of both ALDHhigh
and ALDHlow fractions of the MPM cell lines varies in re-
sponse to cisplatin treatment, plausibly due to the differ-
ences in the pathological subtype given that both H28 and
Meso4 are of a predominantly epitheloid phenotype and
H2052 is sarcomatoid [23].
We further investigated the effect of this drug on the
sphere-forming capacity of the ALDH-sorted fractions as
the generation of spheres after drug treatment would
reflect the presence of drug-tolerant CSCs [19]. After 48-
and 72-h treatments with cisplatin, surviving cells were
collected and incubated in a sphere-permissive medium.
Sphere-forming efficiencies were compared with the non-
treated cells. Figure 4D demonstrates that the 48-h drug
treatment in H28 significantly attenuated sphere forma-
tion which increased after the 72-h drug exposure. In
H2052, 100% elimination of the sphere-forming popula-
tion was observed after 48 h of drug treatment, but unex-
pectedly re-appeared after 72 h (Figure 4E). Meso4
responded with a gradual reduction of the sphere forma-
tion with increased drug incubation time although this
was not completely eliminated. (Figure 4F). Our data dem-
onstrate that both ALDHhigh and ALDHlow fractions of
the MPM cell lines contain cisplatin-resistant sphere-
forming cells. Representative images of sphere-forming
cells of H2052 ALDH-sorted cells before and after
cisplatin treatments are shown in Figure 4G.DEAB treatment prior to cisplatin exposure reduced cell
viability but does not eliminate the sphere-forming cells
in both ALDHhigh and ALDHlow fractions
We hypothesized that specific inhibition of ALDH by
DEAB may sensitize the ALDH-sorted fractions of the
three MPM cell lines as DEAB has been shown to
inhibit ALDH in breast, leukemia and lung cancer cell
lines, as well as the ALDHhigh/CD44+ cells in breast can-
cer [6,14]. The sensitizing effect of DEAB was assessed
by sequential 100 μM DEAB and cisplatin treatments
and were evaluated by cell viability and sphere-forming
efficiency. The 48-h cisplatin + DEAB treatments reduced
cell viability in both ALDHhigh- and ALDHlow-sorted frac-
tions in all three MPM cell lines with remarkable reduc-
tions observed in the ALDHhigh -sorted fractions of H28,
H2052 and Meso4 compared with the cisplatin alone-
treated cells. Prolonged treatment of 72 h markedly di-
minished the cell viability in all of the ALDHhigh cells
compared with the ALDHlow cells which demonstrated a
less pronounced reduction in cell viability (Figure 5A-C).
No decrease in sphere formation was found in H28 after
48 h of cisplatin + DEAB treatment compared with the
cisplatin alone-treated cells (Figure 5D); H2052 main-
tained the absence of spheres, and the sphere-forming
cells were totally eliminated in Meso4. Unexpectedly,
and as previously shown in Figure 4D-F, 72-h incuba-
tion enhanced sphere efficiency in H28-sorted fractions,
with the re-emergence of spheres in the ALDHhigh- and
ALDHlow-sorted H2052 and Meso4 cell lines (Figure 5D-F).
These data indicate that DEAB exerts a marked reduction
in cell viability of the ALDHhigh-sorted cells, but cannot
fully sensitize the drug-resistant sphere-forming cells to
cisplatin.
ALDH isozymes and CD44 mRNA levels increased after
cisplatin + DEAB treatment in both ALDHhigh and ALDHlow
sorted fractions
The failure of cisplatin + DEAB treatment to inhibit
sphere formation led us to examine the drug-resistance
properties of ALDH and CD44 at the transcript level.
We analysed the mRNA levels of the two markers in the
non-treated, cisplatin-treated and cisplatin + DEAB-
treated cells in the ALDH-sorted fractions of the three
MPM cell lines. Aldefluor assay can specifically detect
ALDH1A, ALDH1A2, ALDH1A3 and ALDH2 [6,24].
We therefore evaluated the four ALDH isozymes in the
surviving cells after the drug treatments using qRT-PCR
analysis. Increased mRNA levels after the 72-h cisplatin
+ DEAB treatment reflects drug tolerance as demon-
strated by the re-ermergence of sphere formation.
ALDH1A2 and ALDH1A3 are the predominant iso-
zymes in the three MPM cell lines. In H28, cisplatin +
DEAB treatment reduced ALDH1A3 after 48 h but this
was significantly increased after 72 h. ALDH1A2 was
Figure 4 Effect of cisplatin treatment on ALDH activity and sphere-forming efficiency. Cells in 10 cm dishes were treated with the
previously determined IC50 of cisplatin for ALDH-sorted fractions of the MPM cell lines. After the 48- and 72-h cisplatin treatments of
ALDHhigh- and ALDHlow-sorted cells, ALDH activity (A-C) was determined on surviving cells and compared with the non-treated cells to evaluate
the effect of cisplatin by flow cytometry. The sphere-forming efficiency of the cisplatin-resistant cells was also evaluated as described in the
Methods, and compared with the non-treated cells (D-F). Results represent the means and SDs of 3 independent experiments each. Data are
statistically significant if p <0.05 (*p <0.05, **p <0.01, ***p <0.001). Representative images of spheres from non-treated and cisplatin-treated H2052
ALDHhigh - and H2052 ALDHlow -sorted cells (G).
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H2052 and Meso4, cisplatin + DEAB incubations for
48 h slightly reduced ALDH1A2 and ALDH1A3, but
remarkably, only ALDH1A2 was significantly enhanced
after the 72-h treatment (Figure 6B-C). As expected, cis-
platin + DEAB treatment for 48 h did not confer aninhibitory effect on CD44 in the ALDH-sorted fractions
of H2052 and Meso4, but slightly increased it in H28.
Importantly, CD44 significantly increased in both
ALDH- sorted fractions of H2052 and the Meso4ALDH-
high fraction (Figure 6E-F). Meso4ALDHlow fraction and
H28-sorted fractions also showed higher mRNA levels
Figure 5 Cisplatin + DEAB treatment decreases cell viability and induces a short-term inhibition of sphere formation. ALDHhigh- and
ALDHlow-sorted cells of H28, H2052 and Meso4 were pre-treated with 100 μM DEAB for 48 h, then re-incubated with cisplatin (Cis) for either 48 h
or 72 h. Cell viability of the surviving cells was quantified using tryphan blue exclusion test which was performed in triplicates in 3 independent
experiments (A-C). Surviving cells were allowed to form spheres under an anchorage-independent culture condition which were evaluated on
day 7 and then compared with the non-treated cells (D-F). Results represent means and SDs of 3 experiments with 6 replicates each. Dashed
lines symbolize 0 values. The level of significance was set at p <0.05 (*p <0.05, **p <0.01, ***p <0.001). Representative images of sphere-formation
of ALDHhigh -sorted MPM cell lines, with and without cisplatin treatment, and in the presence or absence of 100 μM DEAB (G). The ALDHlow -sorted
fraction of each cell line showed the same effect (images not shown).
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results highly indicate that ALDH 1A2, ALDH1A3 and
CD44 confer resistance to cisplatin + DEAB; hence, the
cells bearing these markers may partially account for the
re-appearance of spheres after the drug treatment.Discussion
The identification of a chemoresistant population offers
the possibility of cell-specific therapeutic approaches
that may augment the current treatment modalities in
malignant pleural mesothelioma. Here we show that
Figure 6 Cisplatin + DEAB-resistant cells show increased mRNA levels of ALDH isozymes and CD44. mRNA was isolated from non-treated
and surviving cells of the ALDH-sorted fractions of H28, H2052 and Meso4 after cisplatin treatment in the presence or absence of DEAB for 48
and 72 h. Relative mRNA expression levels of ALDH1A2 and ALDH1A3 (A-C) and CD44 (D-F) were determined by qRT-PCR using the ΔΔCT
method. Histograms represent the means and SDs from 3 independent experiments each. Results are statistically significant if p <0.05 (*p <0.05,
***p <0.001).
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ance to cisplatin in the three MPM cell lines; H28,
H2052 and Meso4. We also demonstrate that ALDH as
a single marker is not sufficient to define chemoresis-
tant, sphere-forming cell populations in the tested
MPM cell lines.
Several reports have supported the utility of ALDH to
identify CSC-like populations in different malignancies
and its potential as a therapeutic target [5,8,20,25,26].We found that all MPM cell lines are capable of produ-
cing spheres for three consecutive generations thus sus-
taining the property of self-renewal, a stem cell feature
considered as a key discriminating difference between
CSCs and non-CSCs [27]. The presence of ALDH activ-
ity in H28, H2052 and Meso4 further supports the exist-
ence of putative CSC populations in these cell lines.
Unexpectedly, the ALDHhigh- and ALDHlow-sorted cells
which were supposed to demarcate a CSC- from non-
Cortes-Dericks et al. BMC Cancer 2014, 14:304 Page 11 of 13
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ate ALDH activity although the ALDHlow cells were less
efficient. They also both showed an association with
CD44. Wang et al. [12] and Prasmickaite et al. [22] also
found that ALDHbr/+and ALDHlow/- cells repopulated
stem cell heterogeneity, formed spheroids and generated
tumours in epithelial and malignant melanoma. In the
lung adenocarcinoma cell line, SPC-A1 both ALDHlo
and ALDHhigh-sorted cells formed colonies and devel-
oped tumours although ALDHlo was less efficient [28].
In the MPM cell line, MSTO211H and Ewing’s sarcoma
cell lines only purified ALDHbright cells generated both
ALDHbright/ALDHlow cells, but ALDHlow did not re-
populate ALDHbright cells [21,29]. These studies suggest
that the type of tumour and heterogeneity within a can-
cer [30] are at least in part, responsible for the differen-
tial behavior of ALDH in the malignant setting.
Moreover, ALDH activity may be dependent on whether
the tumour conforms to the cancer stem cell model. The
CSC model proposes the presence of a cellular hierarchy
in the tumour, and that only a subset of tumour cells
possess the ability of self-renewal and to generate the
different phenotypes that comprise the neoplasm [31]. A
conversion of ALDHlow cells into ALDHhigh cells in the
presence of an appropriate environment during the
short-term, in vitro culture is a possible explanation.
This assumption follows the stemness phenotype model
(SPM) proposing that all cancer cells possess stem cell
properties, and that stemness is modulated by the envir-
onment such that CSCs and non-CSCs can interconvert
into each other when changes in the environment fa-
vours this conversion [32]. In support of this hypothesis,
it has been shown that CD44− Du145 prostate cells pro-
duced CD44+ cells in vitro [33], and in the MCF-7 breast
cancer cell line, the sorted non-SP cells gave rise to SP
cells [34]. The question of whether MPM follows the
CSC or SMP model warrants further investigation.
Our findings showed that ALDH activity is resistant to
cisplatin treatment in the ALDH-sorted fractions of the
three MPM cell lines. This consolidates with the bio-
logical function of ALDH in its ability to detoxify antican-
cer drugs such as oxazaphosphorines, cyclophosphamides
and taxanes thus conferring drug resistance [5,7,14]. Con-
sistent with our findings, chemoresistance as an attribute
of ALDH+ cells has been documented in different solid tu-
mours including lung cancer and primary MPM speci-
mens [8,21,26,29,35]. The presence of ALDHhighCD44+
subpopulations in the ALDH-sorted fractions highly indi-
cates that in addition to ALDH, CD44 may also contribute
to cisplatin resistance. The current consensus posits that
CD44+ subfractions in many human cancers are highly
malignant and drug resistant. In non-small cell lung can-
cer, CD44+-sorted cells with stem cell-like properties were
found to be more resistant to cisplatin than CD44− cells[15]. Wang et al. [12] proposed that the combination of
ALDH1 and CD44 stringently defined ovarian cancer
stem cells, which showed chemoresistance and poor
clinical clinical outcome. This is strengthened by the
recent evidence that ALDHhiCD44hi tumour-initiating
cells maintained lung tumorigenicity and drug resist-
ance in patient-derived lung cancer cells [36].
Our results demonstrated that sequential DEAB and
cisplatin treatments remarkably diminished cell viability
in the ALDHhigh-sorted cells, a short-term elimination of
spheres, but not a complete inhibition of sphere forma-
tion in all of the ALDHhigh and ALDHlow fractions of
MPM cell lines. The profound effect of DEAB in the cell
viability of ALDHhigh fractions is supported by the find-
ings which showed that the downregulation of ALDH
isozymes in A549 lung cancer cell line altered cell prolif-
eration and motility, whereas an analogous experiment
in cell lines devoid of ALDH-expressing cells had an
insignificantly less inhibitory effect on cell proliferation
demonstrating a functional role of ALDH in the regulation
of cell growth [9]. Croker and Allan [14] also observed a
significant reduction in cell viability but not a complete in-
hibition of a long-term re-growth of colony-forming ability
of chemo- or radiation-treated ALDHhiCD44+ cells pre-
treated with DEAB in breast cancer. A plausible explan-
ation for the re-emergence of spheres may be attributed
to the survival of putative CSCs which escaped the
cytotoxic effect of cisplatin, and were tolerant to DEAB
treatment. We speculate that the tested MPM cell lines
have a heterogeneous cancer cell population. The more
differentiated cells within the hierarchy might be effi-
ciently killed by chemotherapy, whereas the less differ-
entiated cells bearing CSC phenotypes survive and give
rise to new transit-amplifying cells with the capacity to
regenerate the culture [37]. The possibility of cells exist-
ing in a dormant quiescent state with the capacity to
regrow when the environmental cues are appropriate
could also be an attribute [38]. If the observed cisplatin
resistance is unique to ALDHhigh cells only, then a
DEAB-mediated sensitization process should have pre-
vented the re-growth of spheres. The failure of DEAB to
sensitize both the ALDH-sorted fractions to cisplatin
strongly supports our assumption that the ALDHhighCD44+
cells are crucial players in conveying drug tolerance.
Hence, specific targeting of both phenotypes may offer
a more effective chemotherapy.
Studies have shown that ALDH activity may reflect
other ALDH isozymes in addition to the prevalent
ALDH1A1 which are important in the regulation of
several biological activities including drug resistance
[39,40]. Hence, the identification of specific isozymes
contributing to ALDH activity is a critical factor. We
observed an upregulation of ALDH1A2 in H28 and
ALDH1A3 in H2052 and Meso4 in the cisplatin +
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three MPM cell lines, indicating the implication of these
two isozymes in conveying resistance to cisplatin and
DEAB. Other groups [6,8,28] have detected ALDH1A1,
ALDH1A2, ALDH3A1, and ALDH2A1 in lung cancers
which were shown to have an association with chemore-
sistance. CD44 was likewise increased after an analogous
treatment with cisplatin + DEAB highly suggestive of an
essential role in conferring drug tolerance. Our data
indicate that at the transcript level, ALDH and CD44 are
important players in the observed resistance to cisplatin
and DEAB. Notably, inhibition of ALDH activity cannot
sensitize the ALDHhghCD44+ cells to drug treatment.
Conclusions
In conclusion, we found that both ALDHhigh and ALDHlow
fractions of the three MPM cell lines; H28, H2952 and
Meso4 harboured ALDHhighCD44+ cells that are in-
volved in conferring resistance to cisplatin, and may
therefore serve as potential therapeutic targets to im-
prove the current treatment modalities in MPM. Our
data also demonstrate that the double expression of
ALDH and CD44 rather than ALDH alone better delin-
eates a chemoresistant, sphere-forming cell populations
in the tested MPM cell lines. Further investigations are
necessary to determine the distinct role of ALDHhighCD44+
cells in fueling chemoresistance to other anti-neoplastic
drugs in the treatment of MPM.
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